Clinical trials: Epidermis
Non Small Cell Lung Cancer
Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy
A multi-center, single-arm. Phase 2 exploratory trial to evaluate the efficacy and safety of HM61713 as the 1st-line anticancer agent in none-small cell lung cancer patients with EGFR mutation
- Trial name
- NCT02444819
- Testing
- HM61713
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)
The purpose of the the study is to evaluate the ability of injections of Ji Gami(TM) C to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451151
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Metastatic Breast Cancer
Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea
The objective of this study is to evaluate the real-world prescription patterns of Palbociclib in breast cancer (BC) patients who were treated with Palbociclib in combination with AI as a 1st line of therapy using the national…
- Trial name
- NCT05132101
- Testing
- Patients who received Palbociclib as first line therapy in MBC setting
- Where
- South Korea
- Volunteers
- 2,758 people
- Sponsor
- Pfizer
Breast Cancer
Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan
This is a retrospective, multicenter, observational study in Japan by medical record review of advanced breast cancer (ABC) patients who have received palbociclib plus endocrine therapy (ET) as first line or second line setting.
- Trial name
- NCT05399329
- Testing
- Palbociclib, Endocrine therapy
- Where
- 20 sites in Japan
- Volunteers
- 693 people
- Sponsor
- Pfizer
Locally Advanced or Metastatic NSCLC
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
To assess the efficacy and safety of ASK120067 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor Gefitinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT04143607
- Testing
- ASK120067, Gefitinib
- Where
- 3 sites in China
- Volunteers
- 337 people
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Breast Neoplasms
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
The purpose of study is to determine tolerability and safety profile of H3B-6545 in Japanese women with ER-positive, HER2-negative breast cancer, and also to confirm the dose applicability to Japanese.
- Trial name
- NCT04568902
- Testing
- H3B-6545, Antihistamine
- Where
- 2 sites in Japan
- Volunteers
- 33 people
- Sponsor
- Eisai Co., Ltd.
Metastatic Breast Cancer, Metastatic Solid Cancer
HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
This phase II study aims to confirm the diagnostic performance and accuracy of 68Ga-ABS011 PET/CT in determining the HER2 expression status, and to evaluate 68Ga-ABS011's ability to drive changes in therapeutic treatment.
- Trial name
- HERMIA (NCT06369831)
- Testing
- 68Ga-NOTA-ABSCINT-HER2 PET/CT
- Where
- 7 sites in Austria, Belgium
- Volunteers
- 60 people
- Sponsor
- Abscint NV/SA
Non-Small Cell Lung Cancer
A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC
This is a Phase 1b, open-label, multicentre study of AZD6094 in combination with gefitinib in patients with epidermal growth factor receptor (EGFR) mutation positive (m+) and progressed on EGFR Tyrosine kinase inhibitor (TKI)…
- Trial name
- NCT02374645
- Testing
- Volitinib, gefitinib
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Hutchison Medipharma Limited
Anticancer Treatment
AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase III, Open Label, Randomized Study of Osimertinib versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal…
- Trial name
- AURA3 (NCT02151981)
- Testing
- Chemotherapy, Cross-over to Osimertinib
- Where
- 150 sites in United States, Australia and 16 more
- Volunteers
- 421 people
- Sponsor
- AstraZeneca
Advanced Non-small Cell Lung Cancer, EGFR Mutation
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body.
- Conditions
- Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation
- Trial name
- NCT05099172
- Testing
- BAY2927088_formulation A, BAY2927088_formulation B_1, BAY2927088_formulation B_2
- Where
- 94 sites in United States, Belgium and 14 more
- Volunteers
- 430 people
- Sponsor
- Bayer
Influenza in Human
Comparison of Laser Assisted Epidermal to Intradermal Administration of Seasonal Influenza Vaccine
It is the aim of the present study to compare the immunogenicity induced by a laser-assisted epidermally administered seasonal influenza vaccine to an intradermally administered seasonal influenza vaccine.
- Trial name
- NCT02988739
- Testing
- seasonal influenza vaccine, fractional Er:Yag laser
- Where
- Austria
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pantec Biosolutions AG
Breast Neoplasms
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
This multicenter, two-cohort, non-randomized, open-label study will evaluate the safety and tolerability of assisted and self-administered SC Herceptin as adjuvant therapy in participants with early HER2-positive breast cancer…
- Trial name
- SafeHER (NCT01566721)
- Testing
- Herceptin
- Where
- 437 sites in Albania, Algeria and 57 more
- Volunteers
- 2,577 people
- Sponsor
- Hoffmann-La Roche
Advanced Breast Cancer
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
A study to investigate camizestrant in combination with atirmociclib in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with a…
- Trial name
- SERENA-1b (NCT07427394)
- Testing
- Camizestrant, Atirmociclib
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Epidermal Pigmented Lesions, Skin Toning
Evaluation of the 755nm Alexandrite Laser for Skin Toning and Epidermal Pigmented Lesions in Asian Skin Types
The purpose of this study is to assess treatment for facial skin toning and removal of epidermal pigmented lesions for Asian patients using the 755nm Alexandrite laser
- Trial name
- NCT01754246
- Testing
- 755nm Alexandrite Laser
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cynosure, Inc.
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- LUCERNA (NCT06901531)
- Testing
- zolbetuximab, Pembrolizumab, Capecitabine
- Where
- 252 sites in United States, Australia and 20 more
- Volunteers
- 500 people
- Sponsor
- Astellas Pharma Global Development, Inc.
HER2-positive Breast Cancer
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer
The purpose of the study is to identify molecular markers at the level of molecular pathway activation to predict efficacy of anti-HER2 therapy with Trastuzumab.
- Trial name
- NCT03521245
- Testing
- RNA sequencing, Transcriptome analysis, Trastuzumab
- Where
- 4 sites in United States, Russia
- Volunteers
- 40 people
- Sponsor
- OmicsWay Corp.
HER2-positive Breast Cancer
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.
- Trial name
- BREnnA (NCT07413939)
- Testing
- RO7771950, Tucatinib, Trastuzumab
- Where
- 206 sites in United States, Argentina and 23 more
- Volunteers
- 650 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable…
- Trial name
- NeoADAURA (NCT04351555)
- Testing
- Osimertinib, Cisplatin, Carboplatin
- Where
- 158 sites in United States, Austria and 23 more
- Volunteers
- 358 people
- Sponsor
- AstraZeneca
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
A Study of PF-06873600 in People With Cancer
The purpose of this clinical trial is to learn about the safety and effects of study medicine (PF-06873600) when taken alone or with hormone therapy by people with cancer.
- Trial name
- NCT03519178
- Testing
- PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2
- Where
- 54 sites in United States, Bulgaria and 4 more
- Volunteers
- 155 people
- Sponsor
- Pfizer
Advanced Non Small Cell Lung Cancer
D-0316 First Time in Patients Ascending Dose Study
This is a phase 1 open label multicentre study of D-0316 administered orally in patients with advanced NSCLC who have progressed following prior therapy with an EGFR-TKI (Epidermal Growth Factor Receptor tyrosine kinase inhibitor…
- Trial name
- NCT03452150
- Testing
- D-0316
- Where
- 3 sites in China
- Volunteers
- 84 people
- Sponsor
- InventisBio Co., Ltd